# NEWS RELEASE

## Incubate Bio and Breakpoint Therapeutics announce collaboration to accelerate DNA Damage Response (DDR) drug discovery

- *Breakpoint applying Incubate Bio's AI technologies to advance in-house programmes*
- *Leveraging ALaSCA to generate insights on targets of interest, otherwise difficult to achieve using traditional data science methods*

**London, December 11, 2023** – Incubate Bio (IBI) and Breakpoint Therapeutics announce a collaboration to utilize the ALaSCA software platform to advance Breakpoint's portfolio of DNA Damage Response (DDR) related targets.

"*The ability to gain additional pathway insights holds great promise,*" commented **Dr Daniel Speidel, Managing Director, Breakpoint Therapeutics***. "Working with the multi-disciplinary team at IBI will help us to quickly receive rich interrogatable datasets, enabling us to further execute on our strategy to address this challenging area of biology.*"

Alterations in DDR pathways are prominent in many cancers. Targeting various DDR proteins with novel drugs is therefore an attractive strategy to help patients with difficult-to-treat disease. Considerable amounts of research and data have been generated in and around this burgeoning area of interest, making navigation and assessment of the mass of information available a complex challenge. As an AI-based tool, ALaSCA is ideally suited to supporting researchers in this time consuming and laborious work, without institutional or scientific bias.

**Dr Raminderpal Singh, CEO Incubate Bio** added; "*We were pleased to work with the team at Breakpoint to further validate the ALaSCA platform as a tool for rapid assessment of this area of complex biology. We were able to use both public and propriety information to create unique actionable datasets for Breakpoint that were easy to exploit by their scientific team.*"

ALaSCA applies machine learning and causal AI algorithms and has been validated on omics datasets in molecular pathways. ALaSCA offers a cost-efficient computational approach to help decipher what is happening in molecular pathways of interest and to simulate 'what-if' scenarios for potential drug interventions ahead of costly lab-based experiments. Adoption of the ALaSCA software platform, as an

integral part of preclinical R&D workflow, enables the identification and *in silico* simulation of key drivers in complex biological processes and enhance scientific understanding.

+++ END +++

**About Incubate Bio**

Incubate bio is revolutionizing how R&D scientists explore and simulate effects during preclinical phases. Incubate bio's platform, ALaSCA (patent pending), uses formal causal methods to untangle the pivots and redundancies within biological pathways - thereby enabling the identification of the optimal nodes for drug and other treatment interventions, and improving the efficiency of targeting for any phenotypic (disease) process.

For more about Incubate bio: https://www.incubate.bio/

**About Breakpoint Therapeutics**

Breakpoint Therapeutics is developing targeted cancer therapies that modulate DNA damage response (DDR) pathways. Through precise interference with DNA repair, our drug candidates are designed to kill cancer cells without harming healthy cells. We leverage new insights and the concept of synthetic lethality to increase the therapeutic window and achieve better outcomes for patients with therapy-resistant and hard-to-treat cancers.

For more about Breakpoint Therapeutics: https://breakpointtx.com/